Oral cancer remains among the most prevalent head and neck malignancies worldwide, with survival rates stubbornly low despite improvements in standard treatments such as surgery, radiation, and cisplatin-based chemotherapy. A significant obstacle in treatment is the tumor’s remarkable ability to adapt quickly, developing drug resistance that dampens the efficacy of chemotherapy. While hypoxia’s contribution to tumor aggressiveness and therapy failure has been recognized, the underlying molecular processes by which low oxygen modulates cancer cell signaling have been largely elusive.

The team led by Distinguished Professor Zhiyuan Zhang and Associate Professor Qin Xu has made a pivotal advance by illuminating an unorthodox pathway of EGFR activation driven internally by the cancer cell’s microenvironment rather than by ligand binding or mutation. EGFR is a well-characterized receptor tyrosine kinase that transduces growth signals upon activation by extracellular growth factors, stimulating cell proliferation and survival. However, under hypoxic conditions, this receptor is aberrantly switched on through a post-transcriptional regulatory mechanism orchestrated by EUDAL. This lncRNA binds EGFR directly, preventing it from undergoing ubiquitination and subsequent degradation by the proteasome-lysosome system.

Under physiologic conditions, EGFR protein turnover is tightly controlled by the c-Cbl and Grb2 adaptor proteins, which tag the receptor with ubiquitin molecules to signal its lysosomal clearance. Hypoxia-induced expression of EUDAL interrupts this homeostatic regulation by blocking the ubiquitination step. Consequently, EGFR is stabilized in an active conformation, perpetuating intracellular signaling cascades notably involving the STAT3 and BNIP3 pathways. This continuous activation fosters autophagy—a cellular recycling program that cancer cells exploit to sustain metabolic needs and resist cytotoxic stress from chemotherapy agents like cisplatin.

Functional assays in vitro and in vivo underscored the profound impact of EUDAL on tumor biology. Oral cancer cells expressing high levels of EUDAL exhibited heightened resistance to cisplatin, manifesting enhanced survival despite drug treatment. Conversely, silencing or inhibiting EUDAL restored chemosensitivity, resulting in marked reductions in cell viability. Animal models provided complementary evidence: tumors enriched in EUDAL maintained aggressive growth during cisplatin therapy, but combination treatment targeting STAT3 or the autophagy machinery alongside chemotherapy significantly impeded tumor progression.

Clinical correlations further substantiated the translational relevance of EUDAL. Analysis of tumor biopsies from oral cancer patients undergoing platinum-based chemotherapy revealed that elevated EUDAL, active EGFR, and STAT3 levels were predictive of poor therapeutic response and worse prognoses. This positions EUDAL not only as a mechanistic driver of resistance but also as a potential biomarker to stratify patients unlikely to benefit from conventional chemotherapy protocols. Such stratification could inform personalized treatment regimens, incorporating novel inhibitors that disrupt the EUDAL-EGFR axis or its downstream effectors.

The implications of this discovery extend beyond prognostication. Targeting EUDAL or its associated signaling pathways presents an innovative therapeutic avenue to circumvent hypoxia-induced drug resistance. Given that existing EGFR-directed therapies often rely on blocking extracellular ligand binding or inhibiting kinase activity, exploiting this RNA-mediated stabilization mechanism could address a previously unrecognized route of EGFR activation. This might lead to combination therapies integrating EUDAL antagonists to potentiate chemotherapy response and improve survival outcomes in oral cancer patients.

Moreover, this study reshapes our understanding of how the tumor microenvironment modulates oncogenic signaling networks. It elucidates a noncanonical mode of receptor activation whereby tumor hypoxia triggers intracellular molecular changes independent of extracellular receptor ligands or genetic alterations. This paradigm shift highlights the critical role of lncRNAs as functional regulators in cancer progression and drug resistance. The RNA landscape thus emerges as an underexplored target space with broad implications for oncology research and therapeutic development.

While these findings represent a significant step forward, further investigations are warranted to elucidate the full spectrum of EUDAL’s interactions and regulatory mechanisms in different tumor contexts. Additionally, research into safe and effective approaches to targeting lncRNAs in clinical settings remains a challenge. Advances in RNA-based therapeutics, including antisense oligonucleotides, small molecule inhibitors, or RNA interference technologies, may facilitate translation of these insights into viable treatment strategies.

Ultimately, this discovery shines light on a hidden vulnerability in oral cancer biology—the aberrant stabilization and activation of EGFR through a hypoxia-induced long noncoding RNA. By unveiling the molecular dialogue between oxygen deprivation, lncRNA function, and critical oncogenic pathways, this research paves the way for novel interventions designed to outmaneuver cancer resistance mechanisms. Such breakthroughs offer renewed hope for improving therapeutic efficacy and extending survival for patients battling this devastating disease.

Subject of Research: Cells
Article Title: LncRNA EUDAL shapes tumor cell response to hypoxia induced constitutive EGFR activation and promotes chemoresistance in oral cancer
News Publication Date: 12-Sep-2025
References: DOI: 10.1038/s41368-025-00396-2
Image Credits: Prof. Zhiyuan Zhang and Dr. Qin Xu from Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Keywords: Cancer, Oncology, Drug resistance, Biomarkers, Genetics, Molecular biology, Cell biology, Diseases and disorders, Health and medicine

HER3’s biological significance stems largely from its unique capacity to form functional heterodimers with other ErbB family members, most notably HER2. While HER3 lacks robust intrinsic kinase function, its cytoplasmic domain contains multiple docking sites for the p85 subunit of PI3K, enabling potent activation of the PI3K/Akt signaling cascade upon dimerization. This mechanism allows HER3 to serve as a critical amplifier of downstream signaling pathways, effectively coupling extracellular ligand binding events to intracellular proliferation and survival responses crucial to cancer progression.

The downstream effects of these HER3 heterodimers engage several key oncogenic signaling pathways. Among these are the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/Akt pathways—both instrumental in driving cell cycle progression, preventing programmed cell death, and promoting metastatic dissemination. Aberrant activation of these pathways through HER3 overexpression or mutation has been implicated in the aggressive behavior of various solid tumors, including breast, lung, colorectal, pancreatic, and gynecologic cancers, highlighting HER3’s broad impact across diverse tumor types.

Clinically, elevated HER3 expression correlates strongly with poor patient prognoses and the emergence of resistance to standard therapies. This observation has galvanized efforts to develop HER3-targeted therapeutics, including monoclonal antibodies and small molecules designed to interrupt ligand binding or receptor dimerization. However, despite these targeted interventions, clinical outcomes have often been disappointing. Many trials have failed to demonstrate meaningful efficacy, underscoring the challenges inherent in targeting HER3’s complex biology.

A critical barrier to successful HER3-targeted therapy appears to be the heterogeneity in patient tumor biology. Not all cancers with HER3 expression rely on HER3 signaling equally, and only subsets—characterized by specific biomarkers such as neuregulin-1 (NRG1) gene fusions or high receptor density—show meaningful responses. This realization has prompted calls for improved predictive biomarkers capable of identifying patients whose tumors are “addicted” to HER3 signaling, thereby refining patient selection and enhancing therapeutic impact.

Adding another layer of complexity is the tumor microenvironment, which exerts a profound influence on HER3 activation. Paracrine signals originating from stromal components, particularly fibroblasts and liver endothelial cells, can induce HER3 activity independently of canonical ligands. This non-genetic activation shields tumor cells from targeted therapies and contributes to therapeutic resistance and disease relapse, emphasizing the need for treatment strategies that consider both tumor-intrinsic and microenvironmental factors.

In response to these challenges, antibody-drug conjugates (ADCs) targeting HER3 have emerged as a promising second wave of therapeutic innovation. These conjugates link cytotoxic agents to HER3-specific antibodies, selectively delivering chemotherapy to HER3-positive cells while sparing normal tissues. Early-phase clinical trials in HER3-expressing breast and lung cancers have yielded encouraging results, suggesting that ADCs could overcome previous limitations by effectively eradicating resistant tumor subsets.

These advances also underscore the necessity of incorporating HER3 expression profiling into clinical practice. Precise quantification and qualitative analysis of HER3 levels could guide patient stratification, ensuring that therapies are administered to individuals most likely to benefit. This biomarker-driven approach, paired with novel therapeutic modalities, signals a shift toward precision oncology where HER3 transitions from an elusive target to a central node in personalized cancer treatment algorithms.

Fundamental to this evolving paradigm is an enhanced molecular understanding of HER3. Ongoing research elucidates the intricate interplay between HER3 phosphorylation patterns, dimerization partners, and downstream effectors, revealing therapeutic vulnerabilities that were previously unappreciated. As such, HER3 is gradually being redefined not only as a contributor to oncogenic signaling but also as a viable and dynamic target whose inhibition can disrupt tumor networks at multiple nodes.

In sum, the reevaluation of HER3 reflects broader trends in oncology where “undruggable” targets are revisited with sophisticated tools and deeper biological insight. The convergence of improved diagnostics, refined therapeutic designs—including ADCs and combination regimens—and recognition of microenvironmental influences forms the cornerstone upon which future clinical successes will be built. With these advances, HER3 stands poised to fulfill its promise as a keystone in the fight against treatment-resistant solid tumors.

This emerging narrative offers a compelling example of how revisiting established dogma through rigorous, mechanistic investigation can unlock new therapeutic avenues. HER3’s transition from a neglected receptor to a sought-after target captures the dynamic nature of cancer research and highlights the continuing need for innovation in both the laboratory and clinic. As HER3-targeted agents progress through development, the prospect of translating these discoveries into improved patient outcomes becomes ever more tangible.

Looking ahead, comprehensive integration of HER3 biology into multidimensional treatment frameworks—including combination therapies addressing co-activated pathways and tumor microenvironmental factors—will be essential. Such integrative strategies promise not only to enhance efficacy but also to mitigate resistance mechanisms that have long undermined cancer treatment. The future of HER3-directed therapy, therefore, lies at the intersection of molecular precision and adaptive clinical design, emblematic of next-generation oncology.

Subject of Research: HER3 receptor biology and its role in cancer progression and therapy resistance

Article Title: HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

News Publication Date: 2024 (exact date not specified)

References:
Omkar Desai, Moeez Rathore, Christina S. Boutros, Michel’le Wright, Elizabeth Bryson, Kimberly Curry, Rui Wang, HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway, Genes & Diseases, Volume 12, Issue 4, 2025, Article No. 101354, DOI: 10.1016/j.gendis.2024.101354

Image Credits: Genes & Diseases

Keywords: HER3, ErbB receptor family, cancer progression, therapeutic resistance, antibody-drug conjugates, tumor microenvironment, PI3K/Akt pathway, MAPK pathway, predictive biomarkers, neuregulin-1 (NRG1), precision oncology

Recent advancements in our understanding of cancer biology highlight the potential of exosomal RNA (exRNA) as a revolutionary tool in the diagnosis and treatment of head and neck cancers (HNCs). Researchers from the prestigious SRM Institute of Science and Technology, led by the esteemed Dr. KN Aruljothi, have published a groundbreaking study in the journal ExRNA that explores the pivotal functions of exRNA in HNCs. This study illuminates how these small, molecular messengers, secreted by tumor cells, could redefine the landscape of cancer diagnostics and therapeutic strategies.

Exosomal RNA serves as a potent biomarker, capturing the complexities of tumor behavior and enabling a non-invasive approach to cancer management. Unlike traditional methods that rely on invasive biopsies, the detection and analysis of exRNA from non-invasive sources such as saliva and blood open new avenues for early diagnosis. This innovative method significantly reduces patient discomfort and risks associated with surgical biopsies, allowing for timely intervention and better clinical outcomes.

The mechanisms through which exRNAs drive tumor progression are intricate and multifaceted. Exosomes, the extracellular vesicles that carry exRNA, facilitate communication between cells in the tumor microenvironment, leading to critical alterations in cellular behavior. Within the realm of HNCs, exosomal miRNAs, mRNAs, and long non-coding RNAs (lncRNAs) play crucial roles in modulating key signaling pathways. Notably, these pathways include NF-κB, EGFR, and PI3K/AKT/mTOR, which are intimately linked to tumor survival, proliferation, and metastasis.

The study emphasizes that exRNAs are not merely byproducts of tumor activity; rather, they actively engage in orchestrating cancer progression. For instance, specific miRNAs such as miR-21 and miR-486 have been implicated in promoting not just tumor cell proliferation but also mechanisms that allow cancer cells to evade the host’s immune system. This significant insight alters our fundamental understanding of how tumors manage to thrive despite therapeutic interventions.

Furthermore, the impact of lncRNAs like HOTAIR and MALAT1 cannot be overlooked. These RNA species are crucial mediators of cancer cell invasion and motility, facilitating the spread of cancer within the head and neck regions. As they contribute to the transformation of benign cells into malignant entities, their potential as therapeutic targets becomes increasingly apparent. Therapies that can manipulate the activity or expression of these exosomal RNAs could pave the way for innovative treatment modalities.

A particularly exciting aspect of the study is the exploration of the clinical applications of exRNA analysis in liquid biopsies. The non-invasive collection of saliva and blood presents a formidable opportunity to implement real-time cancer diagnostics effectively. By analyzing the exRNA profile of patients, clinicians could assess cancer status, monitor response to therapy, and detect recurrence earlier than ever before. This paradigm shift towards precision medicine positions exRNAs as not only diagnostic markers but also as substantiated therapeutic targets.

The complexities of the exRNA landscape encompass various classes of RNA. For instance, circular RNAs (circRNAs) and PIWI-interacting RNAs (piRNAs) serve specialized roles in fortifying cancer cells against immune detection while also influencing their resilience against chemotherapy. This adaptation of tumor cells to therapeutic stress poses significant challenges in the effective treatment of HNCs. Nevertheless, a thorough understanding of these RNA classes offers novel opportunities to devise strategies that restore sensitivity to existing treatments.

Another focal point of the research highlights the regulatory influence of exRNAs on major oncogenic pathways. For instance, the NF-κB pathway remains a critical player in inflammation and tumor survival, wherein exRNAs significantly tilt the balance in favor of tumor growth. Considering the intricate web of interactions among the PI3K/AKT/mTOR, EGFR, and TP53 pathways, the research illustrates how exRNAs serve as vital conduits for integrating signals that can either promote or impede cancer progression.

The collaborative nature of exRNA signaling emphasizes that a singular approach may not suffice in addressing the complexities of HNCs. Future therapeutic strategies could benefit from a multimodal approach utilizing both exRNA-based diagnostics and engineered therapies aimed at restoring tumor suppressor pathways or inhibiting oncogenic signals triggered by exRNAs. The promise of engineered exosomes for targeted RNA delivery is yet another frontier that could potentially revolutionize cancer therapy.

The study concludes with a bright outlook for the integration of exRNA profiling into clinical practice, despite existing challenges such as standardizing exosome isolation techniques and pinpointing specific RNA biomarkers. Future research must prioritize these areas, alongside validating the therapeutic efficacy of targeting exRNAs in diverse patient populations. As we uncover the underlying mechanisms that drive exRNA-mediated tumor biology, we inch closer to transforming head and neck cancer management.

Ultimately, the evidence presented by Dr. Aruljothi and his team showcases exosomal RNAs as dynamic players in cancer pathogenesis and highlights their potential to revolutionize diagnostics and treatment. The journey towards harnessing these molecular messengers in the battle against head and neck cancers is just beginning, but the prospects for precision oncology have never seemed more promising. By marrying exRNA-based strategies with existing treatment modalities, clinicians can aspire to offer improved therapeutic outcomes and hope to patients navigating the challenging landscape of HNCs.

As science continues to unravel the complexities of cancer biology, exRNAs stand out as a beacon of hope—a transformative element in the quest for more effective, less invasive cancer care.

Subject of Research: Not applicable
Article Title: RNA cargo in motion: the exosomal connection to head and neck cancers
News Publication Date: 27-Mar-2025
Web References: DOI
References: None available
Image Credits: Department of Genetic Engineering, School of Bioengineering, SRM Kattankulathur, Chennai- 603203

Keywords: MicroRNA, exosomal RNA, head and neck cancers, cancer diagnostics, precision medicine, exosomes, cancer biology.

In a statement reflecting on this critical funding, Giulio Draetta, M.D., Ph.D., who serves as the chief scientific officer at MD Anderson, expressed gratitude for CPRIT’s sustained support of transformative cancer research. Draetta emphasized the importance of this funding in enabling MD Anderson’s renowned scientists and clinicians to deepen their understanding of cancer biology, thereby developing better strategies for prevention, diagnosis, and treatment options. This continued commitment is vital in the ongoing battle against cancer, a disease that affects millions of lives worldwide.

The financial backing from CPRIT has resulted in a staggering cumulative total of over $3.7 billion being disbursed in grants for cancer research since the institute’s establishment. Among the recipients, MD Anderson has garnered more than $675 million, equivalent to approximately 18% of the total funds allocated. This level of support has facilitated the recruitment of more than 324 distinguished cancer researchers to Texas, thus enriching the state’s research landscape. The positive impacts of CPRIT’s funding reach far and wide, as evidenced by the provision of over 10.1 million cancer prevention and early detection services that have benefited residents across all 254 Texas counties.

MD Anderson’s strategic focus on innovative research is evidenced through a diverse array of funded projects. One notable initiative involves leveraging synthetic and collateral lethality in tumors resulting from the loss of the MTAP gene. Led by Dr. Jordi Rodon Ahnert, this project aims to explore novel therapeutic avenues for patients with specific genetic profiles, potentially revolutionizing treatment for this subgroup of cancer. Each research project is tailored with an expectation for substantial contributions to the ever-evolving understanding of cancer dynamics and the refinement of treatment protocols.

Another critical project funded through CPRIT is a randomized clinical trial led by Dr. Neeraj Saini. This investigation explores the application of fecal microbiota transplantation in the context of chimeric antigen receptor therapy, particularly focusing on its role in alleviating antimicrobial-associated dysbiosis. Such exploratory trials are crucial as they bridge the gap between basic science and clinical applications, ultimately fostering a more integrated approach to patient care and therapeutic strategies.

Dr. Jia Wu’s groundbreaking work on serum cell-free DNA methylation and radiomics signatures presents a promising path toward the early detection of recurrence in patients diagnosed with HPV-associated oropharyngeal cancer. This innovative approach utilizes advanced imaging physics techniques combined with molecular data to facilitate timely interventions and improve patient prognoses.

MD Anderson’s research portfolio also includes vital investigations into cancer-related fatigue, particularly among adolescent and young adult brain tumor survivors. Dr. Maria Swartz’s study examines the potential benefits of a tele-exercise intervention, highlighting the importance of addressing not only the physical but also the psychological aspects of cancer survivorship. This research exemplifies the comprehensive approach that modern cancer care necessitates, one that integrates lifestyle interventions alongside conventional treatment modalities.

The implications of these funded projects extend beyond individual therapies; they embody a holistic movement toward understanding cancer from multifaceted perspectives. For instance, Dr. Larissa Meyer’s development of a shared decision-making tool aims to facilitate the adoption of levonorgestrel-releasing intrauterine systems for primary endometrial cancer prevention. This involves a careful analysis of clinical practices combined with patient preferences, ensuring that treatments are not only effective but also acceptable to those they aim to benefit.

Within the realm of diagnostics, Dr. Edwin Ostrin’s exploration of blood-based biomarkers for guiding clinical decision-making regarding pulmonary nodules presents an innovative stride towards personalized medicine. By identifying specific markers in the blood that correlate with clinical outcomes, this research holds the potential to transform how healthcare providers approach lung cancer screening and management.

Understanding the nuances of cancer biology is pivotal in overcoming formidable challenges such as resistance to treatment. Dr. Natalie Vokes’ investigation into the mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer is particularly timely, as it addresses a prevalent issue faced by oncologists worldwide. The examination of molecular and spatial tumor architectures promises to uncover critical insights that may reshape existing paradigms in cancer therapy.

As this research unfolds, MD Anderson also investigates integrative strategies against potential side effects of treatment. The exploration of age-related metastatic competence, led by Dr. Honami Naora, illustrates the intersection of basic research and clinical application. Understanding the biological underpinnings that enable cancer to evade therapeutic interventions is vital in developing effective countermeasures.

All these studies underscore a collaborative effort among MD Anderson’s experts, fueled by the unwavering support from CPRIT. This partnership not only aims to advance the scientific frontier but also ensures that findings translate into real-world applications that improve patient outcomes.

MD Anderson’s ability to emerge as a leader in cancer research owes much to such initiatives backed by CPRIT. With this funding, the institution stands poised to explore new scientific territories that may redefine oncology in the coming years. As these projects commence, they embody a spirit of innovation and hope, reinforcing MD Anderson’s mission to ultimately end cancer.

The journey towards a cancer-free future requires not only innovation and expertise but also an unwavering commitment to translate research into practice. With CPRIT’s continued investment in cancer research, institutions like MD Anderson have the essential tools and resources to confront one of humanity’s most challenging health crises. As these 20 projects and beyond mobilize significant scientific inquiry, the ripple effects will positively impact not just Texas, but the global landscape of oncology.

As cancer research evolves, so too must the methodologies and frameworks within which these inquiries are conducted. The diverse range of studies funded creates a fertile ground for new collaborations and shared insights among scientists and clinicians, fostering an environment where boundaries can be transcended, and innovative solutions can be born. In advocating for multipronged strategies against cancer, MD Anderson, bolstered by CPRIT support, exemplifies a forward-thinking approach grounded in both scientific rigor and compassionate patient care.

Subject of Research: Cancer research initiatives and funding
Article Title: MD Anderson Secures $23 Million in Support for Groundbreaking Cancer Research Projects
News Publication Date: August 2023
Web References: MD Anderson Newsroom
References: Cancer Prevention and Research Institute of Texas (CPRIT)
Image Credits: University of Texas MD Anderson Cancer Center

Keywords: cancer research, CPRIT funding, MD Anderson, molecular biology, clinical trials, cancer treatment, drug resistance, telemedicine, personalized medicine, oncology